Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.85 USD
+0.07 (9.10%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $0.86 +0.01 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Sangamo Therapeutics (SGMO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.17 | $8.00 | $1.00 | 306.41% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Sangamo Therapeutics comes to $3.17. The forecasts range from a low of $1.00 to a high of $8.00. The average price target represents an increase of 306.41% from the last closing price of $0.78.
Analyst Price Targets (6 )
Broker Rating
Sangamo Therapeutics currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy, representing 62.5% of all recommendations. A month ago, Strong Buy represented 62.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/13/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Nicole Germino | Hold | Hold |
2/16/2024 | Wedbush Securities | Andreas Argyrides | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 8 |
Average Target Price | $3.17 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.18 |